Universität zu Köln

Tufa, Tafese Beyene, Fuchs, Andre, Orth, Hans Martin, Luebke, Nadine, Knops, Elena, Heger, Eva, Jarso, Godana, Hurissa, Zewdu, Eggers, Yannik, Haeussinger, Dieter, Luedde, Tom, Jensen, Bjoern-Erik Ole, Kaiser, Rolf and Feldt, Torsten (2022). Characterization of HIV-1 drug resistance among patients with failure of second-line combined antiretroviral therapy in central Ethiopia. HIV Med., 23 (2). S. 159 - 169. HOBOKEN: WILEY. ISSN 1468-1293

Full text not available from this repository.

Abstract

Background As a consequence of the improved availability of combined antiretroviral therapy (cART) in resource-limited countries, an emergence of HIV drug resistance (HIVDR) has been observed. We assessed the prevalence and spectrum of HIVDR in patients with failure of second-line cART at two HIV clinics in central Ethiopia. Methods HIV drug resistance was analysed in HIV-1-infected patients with virological failure of second-line cART using the geno2pheno application. Results Among 714 patients receiving second-line cART, 44 (6.2%) fulfilled the criteria for treatment failure and 37 were eligible for study inclusion. Median age was 42 years [interquartile range (IQR): 20-45] and 62.2% were male. At initiation of first-line cART, 23 (62.2%) were WHO stage III, mean CD4 cell count was 170.6 (range: 16-496) cells/mu L and median (IQR) HIV-1 viral load was 30 220 (7963-82 598) copies/mL. Most common second-line cART regimens at the time of failure were tenofovir disoproxil fumarate (TDF)-lamivudine (3TC)-ritonavir-boosted atazanavir (ATV/r) (19/37, 51.4%) and zidovudine (ZDV)-3TC-ATV/r (9/37, 24.3%). Genotypic HIV-1 resistance testing was successful in 35 (94.6%) participants. We found at least one resistance mutation in 80% of patients and 40% carried a protease inhibitor (PI)-associated mutation. Most common mutations were M184V (57.1%), Y188C (25.7%), M46I/L (25.7%) and V82A/M (25.7%). High-level resistance against the PI ATV (10/35, 28.6%) and lopinavir (LPV) (5/35, 14.3%) was reported. As expected, no resistance mutations conferring integrase inhibitor resistance were detected. Conclusions We found a high prevalence of resistance mutations, also against PIs (40%), as the national standard second-line cART components. Resistance testing before switching to second- or third-line cART is warranted.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Tufa, Tafese Beyene UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuchs, Andre UNSPECIFIED UNSPECIFIED UNSPECIFIED Orth, Hans Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Luebke, Nadine UNSPECIFIED UNSPECIFIED UNSPECIFIED Knops, Elena UNSPECIFIED UNSPECIFIED UNSPECIFIED Heger, Eva UNSPECIFIED UNSPECIFIED UNSPECIFIED Jarso, Godana UNSPECIFIED UNSPECIFIED UNSPECIFIED Hurissa, Zewdu UNSPECIFIED UNSPECIFIED UNSPECIFIED Eggers, Yannik UNSPECIFIED UNSPECIFIED UNSPECIFIED Haeussinger, Dieter UNSPECIFIED UNSPECIFIED UNSPECIFIED Luedde, Tom UNSPECIFIED UNSPECIFIED UNSPECIFIED Jensen, Bjoern-Erik Ole UNSPECIFIED UNSPECIFIED UNSPECIFIED Kaiser, Rolf UNSPECIFIED UNSPECIFIED UNSPECIFIED Feldt, Torsten UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-592201
DOI:	10.1111/hiv.13176
Journal or Publication Title:	HIV Med.
Volume:	23
Number:	2
Page Range:	S. 159 - 169
Date:	2022
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1468-1293
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language IMMUNODEFICIENCY-VIRUS TYPE-1; SUB-SAHARAN AFRICA; HIGH-PREVALENCE; MUTATIONS; OUTCOMES Multiple languages Infectious Diseases Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/59220